Effective immediately Lipigon is announcing Dr. Gisela Sitbon as new Chairman of the Board She is replacing Lars Öhman who will stay as member of the Board of Directors. Sitbon is currently Chairman of the Board at Beactica and stock exchange listed Nanologica. Lipigon is also welcoming Dr. Erik Lund as a new board member. Lund has more than 15 years of experience from the big pharma industry, most recently as director of business development at MSD.
- I am honored to be nominated as new Chairman of the Board. Lipigon is an exciting company with a vision to make its mark within the field of lipid biology. They already achieved a research collaboration with AstraZeneca last year. I am looking forward to working with the Lipigon team and help them fine tune the strategy for the future, says Gisela Sitbon about her appointment.
Competence a key factor in building companies
- Bringing in these experienced external board members is an important step in the process of building a sustainable research based Company, says Lipigon Pharmaceuticals CEO Stefan K. Nilsson.
Gisela Sitbon has been involved in the life science industry at senior level for well over 25 years. She has vast experience from early stage companies and she has recently taken part in bringing two companies to the stock market.
Big pharma expertise a welcome addition
The second newly appointed member of the Lipigon board is Erik Lund. He brings the sought-after big pharma perspective to Lipigon and will play an important role in Lipigon’s strategic development.
- These are two strong additions to the Board of Directors that I think complement the existing board very well.” says CEO and Lipigon co-founder Stefan K Nilsson.
About Lipigon Pharmaceuticals
About Lipigon Lipigon is a spin out from Umeå University in Sweden. The company was founded by leading scientists in the field of cellular lipid transport. Lipigon is focusing on the discovery and development of novel treatments for lipid disorders and related diseases. For more information please visit:
For further information, please contact: Stefan K. Nilsson, CEO, Lipigon Pharmaceuticals e-mail:
Tel: +46 70 578 176
The original press release from the company can be found here:
Back to news list